• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Pathog . Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures fer

tetano

Editor, Senior Moderator
PLoS Pathog


. 2021 May 6;17(5):e1009527.
doi: 10.1371/journal.ppat.1009527. Online ahead of print.
Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model


Leo Yy Lee[SUP] 1 [/SUP], Jie Zhou[SUP] 2 [/SUP], Paulina Koszalka[SUP] 1 3 [/SUP], Rebecca Frise[SUP] 2 [/SUP], Rubaiyea Farrukee[SUP] 4 [/SUP], Keiko Baba[SUP] 5 [/SUP], Shahjahan Miah[SUP] 6 [/SUP], Takao Shishido[SUP] 5 [/SUP], Monica Galiano[SUP] 7 [/SUP], Takashi Hashimoto[SUP] 5 [/SUP], Shinya Omoto[SUP] 5 [/SUP], Takeki Uehara[SUP] 5 [/SUP], Edin J Mifsud[SUP] 1 4 [/SUP], Neil Collinson[SUP] 8 [/SUP], Klaus Kuhlbusch[SUP] 9 [/SUP], Barry Clinch[SUP] 8 [/SUP], Steffen Wildum[SUP] 9 [/SUP], Wendy S Barclay[SUP] 2 [/SUP], Aeron C Hurt[SUP] 1 4 9 [/SUP]



Affiliations
Free article

Abstract

Baloxavir is approved in several countries for the treatment of uncomplicated influenza in otherwise-healthy and high-risk patients. Treatment-emergent viruses with reduced susceptibility to baloxavir have been detected in clinical trials, but the likelihood of widespread occurrence depends on replication capacity and onward transmission. We evaluated the fitness of A/H3N2 and A/H1N1pdm09 viruses with the polymerase acidic (PA) I38T-variant conferring reduced susceptibility to baloxavir relative to wild-type (WT) viruses, using a competitive mixture ferret model, recombinant viruses and patient-derived virus isolates. The A/H3N2 PA/I38T virus showed a reduction in within-host fitness but comparable between-host fitness to the WT virus, while the A/H1N1pdm09 PA/I38T virus had broadly similar within-host fitness but substantially lower between-host fitness. Although PA/I38T viruses replicate and transmit between ferrets, our data suggest that viruses with this amino acid substitution have lower fitness relative to WT and this relative fitness cost was greater in A/H1N1pdm09 viruses than in A/H3N2 viruses.
 
Back
Top Bottom